Home Hengrui Pharma's HRS-1635 Tablets Receive Clinical Trial Approval from China's NMPA for B-cell Malignancies

Hengrui Pharma's HRS-1635 Tablets Receive Clinical Trial Approval from China's NMPA for B-cell Malignancies

May 26, 2026 16:49 CST Updated 18:28
Hengrui Pharma

Innovative and High-Quality Pharmaceutical Developer